Immune response to herpes simplex virus and γ134.5 deleted HSV vectors

Current Gene Therapy

Volumn 5, Issue 5, 2005, Pages 523-530

  Broberg, Eeva K ^a   Hukkanen, Veijo ^b  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; GROWTH FACTOR; INFECTED CELL PROTEIN 34.5; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; APOPTOSIS; BRAIN TUMOR; CANCER THERAPY; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DELETION MUTANT; DNA VIRUS; GENE DELETION; GENE EXPRESSION; GENE THERAPY; GLIOMA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; TH1 CELL; TH2 CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REPLICATION; WILD TYPE;

ANIMALS; CYTOKINES; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED BALB C; SIMPLEXVIRUS; TH1 CELLS; TH2 CELLS; TRANSGENES; VIRAL PROTEINS;

DNA VIRUSES; SIMPLEXVIRUS;

EID: 26844541177     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652305774329267     Document Type: Review

References (103)

1. Alvord, E.C., Kies, M.W. & Suckling, A.J. (1984). Experimental allergic encephalomyelitis: A model for multiple sclerosis. Prog. Clin. Biol. Res. 146, 1-8.
2. Andreansky, S., He, B., Gillespie, G.Y., Soroceanu, L., Markert, J., Chou, J., Roizman, B. & Whitley, R.J. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA 93, 11313-11318.
3. Ashkar, A.A., Yao, X.D., Gill, N., Sajic, D., Patrick, A.J. & Rosenthal, K.L. (2004). Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190, 1841-1849.
4. Bartfai, T. & Schultzberg, M. (1993). Cytokines in neuronal cell types. Neurochem. Int. 22, 435-444.
5. Bouley, D.M., Kanangat, S., Wire, W. & Rouse, B.T. (1995). Characterization of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-γ knockout mice. J. Immunol. 155, 3964-3971.
6. Bowers, W.J., Olschowka, J.A. & Federoff, H.J. (2003). Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther. 10, 941-945.
7. 134.5-negative herpes simplex virus type 1 vectors in BALB/c mice. J. Virol. 78, 13139-13152.
8. Broberg, E., Setälä, N., Erälinna, J.-P., Salmi, A., Röyttä, M. & Hukkanen, V. (2002). Herpes simplex virus type 1 infection induces upregulation of IL-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice. J. Interferon Cytokine Res. 22, 641-651.
9. Broberg, E., Setälä, N., Röyttä, M., Erälinna, J.-P., Salmi, A., He, B., Roizman, B. & Hukkanen, V. (2001). Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther. 8, 769-777.
10. Brockman, M. & Knipe, D.M. (2002). Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J. Virol. 76, 3678-3687.
11. Brombacher, R., Kastelein, R.A. & Alber, G. (2003). Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24, 207-212.
12. Burton, E.A., Bai, Q., Goins, W.F. & Glorioso, J.C. (2002). Replication-defective genomic herpes simplex vectors: design and production. Curr. Opin. Biotechnol. 13, 424-428.
13. Burton, E.A., Hong, C.S. & Glorioso, J.C. (2003). The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells. J. Virol. 77, 3516-3530.
14. Carr, D.J., Harle, P. & Gebhardt, B.M. (2001). The immune response to ocular herpes simplex virus type 1 infection. Exp. Biol. Med. 226, 353-366.
15. Chambers, R., Gillespie, G.Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B. & Whitley, R. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92, 1411-1415.
16. Chee, A.V. & Roizman, B. (2004). Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites. J. Virol. 78, 4185-4196.
17. Chen, D., Murphy, B., Sung, R. & Bromberg, J.S. (2003). Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther. 10, 991-998.
18. 134.5 protein of herpes simplex virus 1 are required for viral resistance to interferon-α /β. Virology 290, 115-120.
19. Cheng, G., Feng, Z. & He, B. (2005). Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein. J. Virol. 79, 1379-1388.
20. 134.5 protein of herpes simplex virus type 1 is required for viral response to interferon but is not sufficient for efficient viral replication. J. Virol. 77, 10154-10161.
21. 134.5 a gene nonessential for growth in culture. Science 250, 1262-1266.
22. 134.5 gene of herpes simplex virus 1 precludes neuroblastoma. cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl. Acad. Sci. USA 89, 3266-3270.
23. Cooper, A.M., Kipnis, A., Turner, J., Magram, J., Ferrante, J. & Orme, I.M. (2002), Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol. 168, 1322-1327.
24. Delman, K., Bennett, J., Zager, J., Burt, B., McAuliffe, P., Petrowsky, H., Kooby, D., Hawkins, W., Horsburgh, B., Johnson, P. & Fong, Y. (2000). Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gen. Ther. 11, 2465-2472.
25. Elkins, K.L., Cooper, A., Colombini, S.M., Cowley, S.C. & Kieffer, T.L. (2002). In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect. Immun. 70, 1936-1948.
26. Furlan, R., Brambilla, E., Ruffini, F., Poliani, P.L., Bergami, A., Marconi, P.C,, Franciotta, D.M., Penna, G., Comi, G., Adorini, L. & Martino, G. (2001). Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167, 1821-1829.
27. Geiger, K.D., Nash, T.C., Sawyer, S., Krahl, T., Patstone, G., Reed, J.C., Krajewski, S., Dalton, D., Buchmeier, M.J. & Sarvetnick, N. (1997). Interferon-γ protects against herpes simplex virus type 1-mediated neuronal death. Virology 238, 189-197.
28. Ghiasi, H., Osorio, Y., Perng, G.C., Nesburn, A.B. & Wechsler, S.L. (2001). Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice. J. Virol. 75, 9029-9036.
29. Glorioso, J.C., Mata, M. & Fink, D.J. (2003). Therapeutic gene transfer to the nervous system using viral vectors. J. Neurovirol. 9, 165-172.
30. L flanking repeats. J. Virol. 68, 2239-2252.
31. Goins, W.F., Wolfe, D., Krisky, D., Bai, Q., Burton, E., Fink, D. & Glorioso, J. (2003). Delivery using herpes simplex virus. In Methods in Molecular Biology: Gene Delivery to mammalian Cells: Vol.2. Viral. Gene Transfer Techniques, pp. 257-299. Edited by W. Heiser. Totowa, NJ: Humana Press, Inc.
32. Goins, W.F., Yoshimura, N., Phelan, M.W., Yokoyama, T., Fraser, M.O., Ozawa, H., Bennett N,J.R., de Groat, W.C., Glorioso, J.C. & Chancellor, M.B. (2001). Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J. Urol. 165, 1748-1754.
33. Halford, W.P., Gebhardt, B.M. & Carr, D.J. (1997a). Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1. Virology 238, 53-63.
34. Halford, W.P., Veress, L.A., Gebhardt, B.M. & Carr, D.J. (1997b). Innate and acquired immunity to herpes simplex virus type 1. Virology 236, 328-337.
35. Han, X., Lundberg, P., Tanamachi, B., Openshaw, H., Longmate, J. & Cantin, E. (2001). Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J. Virol. 75, 3048-3052.
36. Harrow, S., Papanastassiou, V., Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S.M. & Rampling, R. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11, 1648-1658.
37. 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 94, 843-848.
38. He, J., Ichimura, H., Iida, T., Minami, M., Kobayashi, K., Kita, M., Sotozono, C., Tagawa, Y.I., Iwakura, Y. & Imanishi, J. (1999). Kinetics of ccytokine production in the cornea. and trigeminal ganglion of C57BL/6 mice after corneal HSV-1 infection. J. Interferon Cytokine Res. 19, 609-615.
39. Hendricks, R.L., Weber, P.C., Taylor, J.L., Koumbis, A., Tumpey, T.M. & Glorioso, J.C. (1991). Endogenously produced interferon alpha protects mice from herpes simplex virus type 1 corneal disease. J. Gen. Virol 72 (Pt 7), 1601-1610.
40. Holterman, A.X., Rogers, K., Edelmann, K., Koelle, D.M., Corey, L. & Wilson, C.B. (1999). An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection. J. Virol. 73, 2058-2063.
41. Hopkins, S.J. & Rothwell, N.J. (1995). Cytokines and the nervous system I: expression and recognition. TINS 18, 83-88.
42. Hu, M., Dutt, J., Arrunategui Correa, V., Baltatzis, S. & Foster, C.S. (1999). Cytokine mRNA in BALB/c mouse corneas infected with herpes simplex virus. Eye 13, 309-313.
43. Hukkanen, V., Broberg, E., Erälinna, J.-P. & Salmi, A. (2002). Cytokines in experimental herpes simplex virus infection. Intern. Rev. Immunol. 21, 355-371.
44. Ikemoto, K., Pollard, R.B., Fukumoto, T., Morimatsu, M. & Suzuki, F. (1995). Small amounts of exogenous IL-4 increase the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1. J. Immunol. 155, 1326-1333.
45. Jackson, R., Ramsay, A., Christensen, C., Beaton, S., Hall, D. & Ramshaw, I. (2001). Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75, 1205-1210.
46. Jing, X., Cerveny, M., Yang, K. & He, B. (2004). Replication of herpes simplex virus 1 depends on the gamma 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection. J. Virol. 78, 7653-7666.
47. Johnson, D.C., Frame, M.C., Ligas, M.W., Cross, A.M. & Stow, N.D. (1988). Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J. Virol. 62, 1347-1354.
48. Kanangat, S., Thomas, J., Gangappa, S., Babu, J.S. & Rouse, B.T. (1996). Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection. J. Immunol. 156, 1110-1116.
49. Keadle, T.L. & Stuart, P.M. (2005). Interleukin-10 (IL-10) ameliorates corneal disease in a mouse model of recurrent herpetic keratitis. Microb. Pathog. 38, 13-21.
50. Kesari, S., Lasner, T.M., Balsara, K.R., Randazzo, B.P., Lee, V.M., Trojanowski, J.Q. & Fraser, N.W. (1998). A neuroattenuated ICP34.5 deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol. 79, 525-536.
51. Khanna, K.M., Bonneau, R.H., Kinchington, P.R. & Hendricks, R.L. (2003). Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18, 593-603.
52. Khanna, K.M,, Lepisto, A.J., Decman, V. & Hendricks, R.L. (2004). Immune control of herpes simplex virus during latency. Curr. Opin. Immunol. 16, 463-469.
53. Kodukula, P., Liu, T., Rooijen, N.V., Jager, M.J. & Hendricks, R.L. (1999). Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J. Immunol. 162, 2895-2905.
54. Koelle, D.M., Reymond, S.N., Chen, H., Kwok, W.W., McClurkan, C., Gyaltsong, T., Petersdorf, E.W., Rotkis, W., Talley, A.R. & Harrison, D.A. (2000). Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J. Virol 74, 10930-10938.
55. Krug, A., Luker, G.D., Barchet, W., Leib, D.A., Akira, S. & Colonna, M. (2004). Herpes simplex virus type 1 (HSV-1) activates murine natural interferon-producing cells (IPC) through toll-like receptor 9. Blood 103, 1433-1437.
56. Kubat, N.J., Amelio, A.L., Giordani, N.V. & Bloom, D.C. (2004). The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency independently of LAT transcription. J. Virol. 78, 12508-12518.
57. Lankford, C.S. & Frucht, D.M. (2003). A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 73, 49-56.
58. Lasner, T.M., Tal-Singer, R., Kesari, S., Lee, V.M., Trojanowski, J.Q. & Fraser, N.W. (1998). Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J. Neurovirol. 4, 100-105.
59. Leib, D.A., Harrison, T.E., Laslo, K.M., Machalek, M.A., Moorman, N.J. & Virgin, H.W. (1999). Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189, 663-67.
60. Lekstrom Himes, J.A., LeBlanc, R.A., Pesnicak, L., Godleski, M. & Straus, S.E. (2000). Gamma interferon impedes the establishment of herpes simplex virus type 1 latent infection but has no impact on its maintenance or reactivation in mice. J. Virol. 74, 6680-6683.
61. Lewandowski, G. & Hobbs, M.V. (1998). Evidence for deficiencies in intracerebral cytokine production, adhesion molecule induction, and T cell recruitment in herpes simplex virus type-2 infected mice. J. Neuroimmunol. 81, 58-65.
62. Liu, T., Khanna, K.M., Chen, X., Fink, D.J. & Hendricks, R.L. (2000). CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191, 59-1466.
63. Liu, T., Tang, Q. & Hendricks, R.L. (1996). Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J. Virol. 70, 264-271.
64. Lubinski, J., Wang, L., Mastellos, D., Sahu, A., Lambris, J.D. & Friedman, H.M. (1999). In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J. Exp. Med. 190, 1637-1646.
65. Lubinski, J.M., Jiang, M., Hook, L., Chang, Y., Sarver, C., Mastellos, D., Lambris, J.D., Cohen, G.H., Eisenberg, R.J. & Friedman, H.M. (2002). Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J. Virol. 76, 9232-9241.
66. Lubinski, J.M., Wang, L., Soulika, A.M., Burger, R., Wetsel, R.A., Colten, H., Cohen, G.H., Eisenberg, R.J., Lambris, J.D. & Friedman, H.M. (1998). Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72, 8257-8263.
67. Lund, J., Sato, A., Akira, S., Medzhitov, R. & Iwasaki, A. (2003). Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198, 513-520.
68. MacLean, A., Wei, X.Q., Huang, F.P., Al Alem, U.A., Chan, W.L. & Liew, F.Y. (1998). Mice lacking inducible nitric-oxide synthase are more susceptible to herpes simplex virus infection despite enhanced Th1 cell responses. J. Gen. Virol. 79, 825-830.
69. Mao, H. & Rosenthal, K.S. (2003). Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential. J. Virol. 77, 3409-3417.
70. Markert, J., Malick, A., Coen, D. & Martuza, R. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32, 597-603.
71. Markert, J., Medlock, M., Rabkin, S., Gillespie, G., Todo, T., Hunter, W., Palmer, C., Feigenbaum, F., Tornatore, C., Tufaro, F. & Martuza, R. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867-874.
72. Markovitz, N.M. & Roizman, B. (2000). Replication-competent herpes simplex viral vectors for cancer therapy. Adv. Virus. Res 55, 409-424.
73. Martino, G., Furlan, R., Comi, G. & Adorini, L. (2001). The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol. 22, 483-490.
74. Martino, G., Poliani, P.L., Furlan, R., Marconi, P., Glorioso, J.C., Adorini, L. & Comi, G. (2000). Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J. Neuroimmunol. 107, 184-190.
75. Miller, C.G. & Fraser, N.W. (2003). Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol. Ther. 7, 741-747.
76. Morrison, L.A. (2004). The Toll of herpes simplex virus infection. Trends Microbiol. 12, 353-356.
77. Natsume, A., Mata, M., Goss, J., Huang, S., Wolfe, D., Oligino, T., Glorioso, J. & Fink, D.J. (2001). Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp. Neurol. 169, 231-238.
78. Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., Zonin, F., Vaisberg, E., Churakova, T., Liu, M., Gorman, D., Wagner, J., Zurawski, S., Liu, Y., Abrams, J.S., Moore, K.W., Rennick, D., de Waal Malefyt, R., Hannum, C., Bazan, J.F. & Kastelein, R.A. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725.
79. Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R. & Brown, M. (2002). The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9, 398-406.
80. Park, A.Y. & Scott, P. (2001). IL-12: keeping cell-mediated immunity alive. Scand. J. Immunol 53, 529-532.
81. Parker, J., Gillespie, G.Y., Love, C., Randall, S., Whitley, R. & Markert, J. M. (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA 97, 2208-2213.
82. Pirhonen, J., Matikainen, S. & Julkinen, I. (2002). Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J. Immunol. 169, 5673-5678.
83. Poliani, P., Brok, H., Furlan, R., Ruffini, F., Bergami, A,, Desina, G., Marconi, P., Rovaris, M., Uccelli, A., Glorioso, J., Penna, G., Adorini, L., Comi, G., 't Hart, B. & Martino, G. (2001). Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum. Gen. Ther. 12, 905-920.
84. Posavad, C., Wald, A., Hosken, N., Huang, M., Koelle, D., Ashley, R. & Corey, L. (2003). T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J. Immunol. 170, 4380-4388.
85. Posavad, C.M., Koelle, D.M. & Corey, L. (1998). Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat. Med. 4, 381-382.
86. Puskovic, V., Wolfe, D., Goss, J., Huang, S., Mata, M., Glorioso, J.C. & Fink, D.J. (2004). Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol. Ther. 10, 67-75.
87. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R. & Brown, M. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene. Ther. 7, 859-866.
88. Riffault, S., Carrat, C., Milon, G., Charley, B. & Colle, J.H. (2000). Transient IFN-γ synthesis in the lymph node draining a dermal site loaded with UV-irradiated herpes simplex virus type 1: an NK- and CD3-dependent process regulated by IL-12 but not by IFN-α /β. J. Gen. Virol. 81, 2365-2373.
89. Roizman, B. & Knipe, D.M. (2001). Herpes simplex viruses and their replication. In Fields. Virology, 4. edn, pp. 2399-2459. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, M. A, Martin, R. A. Lamb, B. Roizman & S. E. Straus. Philadelphia: Lippincott Williams & Wilkins.
90. Rueger, M., Winkeler, A., Miletic, H., Kaestle, C., Richter, R., Schneider, G., Hilker, R., Heneka, M., Ernestus, R., Hampl, J., Fraefel, C. & Jacobs, A.H. (2005). Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther. 12, 588-596.
91. Rux, A.H., Lou, H., Lambris, J.D., Friedman, H.M., Eisenberg, R.J. & Cohen, G.H. (2002). Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. Virology 294, 324-332.
92. Shimeld, C., Easty, D.L. & Hill, T.J. (1999). Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and cytokines. J. Virol. 73, 1767-1773.
93. Shimeld, C., Whiteland, J.L., Williams, N.A., Easty, D.L. & Hill, T.J. (1997). Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1. J. Gen. Virol. 78, 3317-3325.
94. Smith, P.M., Wolcott, R.M., Chervenak, R. & Jennings, S.R. (1994). Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-γ (IFN-γ). Virology 202, 76-88.
95. Stumpf, T.H., Shimeld, C., Easty, D.L. & Hill, T.J. (2001). Cytokine production in a murine model of recurrent herpetic stromal keratitis. Invest. Ophthal. Vis. Sci. 42, 372-378.
96. Trgovcich, J., Johnson, D. & Roizman, B. (2002). Cell surface major histocompatibility complex class II proteins are regulated by the products of the gamma(1)34.5 and U(L)41 genes of herpes simplex virus 1. J. Virol. 76, 6974-6986.
97. Tscharke, D.C. & Simmons, A. (1999). Anti-CD8 treatment alters interleukin-4 but not interferon-γ mRNA levels in murine sensory ganglia during herpes simplex virus infection. Brief report. Arch. Virol. 144, 2229-2238.
98. Välimaa, H., Waris, M., Hukkanen, V., Blankenvoorde, M.F., Nieuw Amerongen, A.V. & Tenovuo, J. (2002). Salivary defense factors in herpes simplex virus infection. J. Dent. Res. 81, 416-421.
99. Wakimoto, H., Johnson, P. R., Knipe, D.M. & Chiocca, E.A. (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10, 983-990.
100. 134.5 deletion mutants in rodent models. J. Chn. Invest. 91, 2837-2843.
101. Whitley, R.J. (2001). Herpes simplex viruses. In Fields Virology, 4. edn, pp. 2461-2509. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, M. A. Martin, R. A. Lamb, B. Roizman & S. E. Straus. Philadelphia: Lippincott Williams & Wilkins.
102. Wiekowski, M.T., Leach, M.W., Evans, E.W., Sullivan, L., Chen, S.C., Vassileva, G., Bazan, J.F., Gorman, D.M., Kastelein, R.A., Narula, S. & Lira, S.A. (2001). Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166, 7563-7570.
103. Yan, X.T., Zhuang, M., Oakes, J.E. & Lausch, R.N. (2001). Autocrine action of IL-10 suppresses proinflammatory mediators and inflammation in the HSV-1-infected cornea. J. Leukoc. Biol. 69, 149-157.